Search - tctmd.com

Displaying 41 - 60 of 250

Sort: Relevancy | Date

News Daily News

ILLUMENATE EU: No Higher Paclitaxel-Related Deaths as Talk Turns to Patency

L.A. McKeown

July 02, 2020

News Daily News

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

L.A. McKeown

June 29, 2020

News Daily News

Abre Venous Stent Meets 30-Day, 1-Year Targets in Pivotal IDE Trial

Caitlin E. Cox

June 18, 2020

News Daily News

TICONC: Ticagrelor May Cut Tumor-Induced Platelet Aggregation in Cancer Patients

L.A. McKeown

June 17, 2020

Lancet COVID-19 Hydroxychloroquine Study Faces ‘Data Integrity’ Questions

News Daily News

TAVR Bests Surgical Redo for Failed Bioprostheses: Early Data

Michael O'Riordan

June 01, 2020

News Daily News

Recovered Paclitaxel PAD Data Shift the Mortality Picture

L.A. McKeown

May 14, 2020

News Daily News

Late Cerebrovascular Events ‘Devastating’ in TAVR-Treated Patients

Michael O'Riordan

March 11, 2020

News Daily News

ViV TAVR Bests Redo Surgery for Failed Valves: Retrospective Study

Yael L. Maxwell

January 16, 2020

News Daily News

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

Michael O'Riordan

November 05, 2019

News Daily News

More Acute Stent Thrombosis With Synergy Stent in Bern PCI Registry

Michael O'Riordan

August 14, 2019

News Daily News

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

L.A. McKeown

June 10, 2019

News Daily News

Vici Venous Stent Receives FDA Approval for Iliofemoral Obstructive Disease

L.A. McKeown

May 06, 2019

News Daily News

Help, Not Harm: Omega-6 PUFAs Linked With Lower Risk of CVD Events

Michael O'Riordan

April 18, 2019

News Daily News

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

L.A. McKeown

March 15, 2019

News Daily News

Could PET Imaging Be the ‘Game Changer’ for Detecting and Predicting Bioprosthetic Valve Degeneration?

Michael O'Riordan

March 13, 2019

News Daily News

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

L.A. McKeown

March 01, 2019

News Daily News

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

L.A. McKeown

February 20, 2019

News Daily News

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

L.A. McKeown

February 13, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

Advertisement

ILLUMENATE EU: No Higher Paclitaxel-Related Deaths as Talk Turns to Patency

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

Abre Venous Stent Meets 30-Day, 1-Year Targets in Pivotal IDE Trial

TICONC: Ticagrelor May Cut Tumor-Induced Platelet Aggregation in Cancer Patients

TAVR Bests Surgical Redo for Failed Bioprostheses: Early Data

Recovered Paclitaxel PAD Data Shift the Mortality Picture

Late Cerebrovascular Events ‘Devastating’ in TAVR-Treated Patients

ViV TAVR Bests Redo Surgery for Failed Valves: Retrospective Study

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

More Acute Stent Thrombosis With Synergy Stent in Bern PCI Registry

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

Vici Venous Stent Receives FDA Approval for Iliofemoral Obstructive Disease

Help, Not Harm: Omega-6 PUFAs Linked With Lower Risk of CVD Events

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

Could PET Imaging Be the ‘Game Changer’ for Detecting and Predicting Bioprosthetic Valve Degeneration?

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content